Cargando…
Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies
BACKGROUND: Attenuated oncolytic measles virus (OMV) is a promising antitumor agent in early-phase clinical trials. However, pre-existing immunity against measles might be a hurdle for OMV therapy. METHODS: OMV was inactivated with short-wavelength ultraviolet light (UV-C). Loss of replication and o...
Autores principales: | Xu, Chun, Goß, Annika Verena, Dorneburg, Carmen, Debatin, Klaus-Michael, Wei, Jiwu, Beltinger, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933358/ https://www.ncbi.nlm.nih.gov/pubmed/29750140 http://dx.doi.org/10.2147/OV.S150637 |
Ejemplares similares
-
Mitophagy switches cell death from apoptosis to necrosis in NSCLC cells treated with oncolytic measles virus
por: Xia, Mao, et al.
Publicado: (2014) -
Oncolytic measles virus enhances antitumour responses of adoptive CD8(+)NKG2D(+) cells in hepatocellular carcinoma treatment
por: Chen, Aiping, et al.
Publicado: (2017) -
The survivin-ran inhibitor LLP-3 decreases oxidative phosphorylation, glycolysis and growth of neuroblastoma cells
por: Galiger, Celimene, et al.
Publicado: (2023) -
Measles Virus as an Oncolytic Immunotherapy
por: Engeland, Christine E., et al.
Publicado: (2021) -
Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy
por: Xia, Mao, et al.
Publicado: (2019)